explore -WSS

explore

author：knowledge 2025-10-02 05:21:57 Page View：124

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug for rare kidney disease narrowly misses mark in clinical trial
Next article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

explore

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Microbiome research is starting to find links to chronic diseases

AdobeWeneverwalkalone.Acrossthelandscapeofourbodies,trillionsofmicrobesaccompanyusonthejourneyoflife

Continuity nursing helped my family in our darkest PICU moments

EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

Senate HELP committee spars over health care workforce policies

Sen.BillCassidy(R-La.),left,andSen.BernieSanders(I-Vt.),right,clashedoverabilltoincreaseranksinthehe

explore

leisure time

explore

Senate HELP committee spars over health care workforce policies